| Code | CSB-RA012145MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Olinvacimab, targeting KDR (Kinase Insert Domain Receptor), also known as VEGFR-2 (Vascular Endothelial Growth Factor Receptor 2). KDR is a critical receptor tyrosine kinase that mediates VEGF-induced endothelial cell proliferation, migration, and survival, playing a central role in both physiological and pathological angiogenesis. This receptor is highly expressed on vascular endothelial cells and is essential for tumor neovascularization, making it a key therapeutic target in oncology. Aberrant KDR signaling has been implicated in various malignancies, including colorectal cancer, non-small cell lung cancer, and other solid tumors, as well as in ocular neovascular diseases.
Olinvacimab is a therapeutic monoclonal antibody designed to inhibit VEGF-mediated KDR activation, thereby blocking angiogenic signaling pathways. This biosimilar provides researchers with a valuable tool for investigating VEGF/VEGFR-2 signaling mechanisms, studying tumor angiogenesis, evaluating anti-angiogenic strategies, and exploring vascular biology in various disease models.
There are currently no reviews for this product.